Ebpay生命医药出版社

Ebpay生命

102677

论文已发表

提 交 论 文


注册即可获取Ebpay生命的最新动态

注 册



IF 收录期刊



  • 3.4 Breast Cancer (Dove Med Press)
  • 3.2 Clin Epidemiol
  • 2.6 Cancer Manag Res
  • 2.9 Infect Drug Resist
  • 3.7 Clin Interv Aging
  • 5.1 Drug Des Dev Ther
  • 3.1 Int J Chronic Obstr
  • 6.6 Int J Nanomed
  • 2.6 Int J Women's Health
  • 2.9 Neuropsych Dis Treat
  • 2.8 OncoTargets Ther
  • 2.0 Patient Prefer Adher
  • 2.2 Ther Clin Risk Manag
  • 2.5 J Pain Res
  • 3.0 Diabet Metab Synd Ob
  • 3.2 Psychol Res Behav Ma
  • 3.4 Nat Sci Sleep
  • 1.8 Pharmgenomics Pers Med
  • 2.0 Risk Manag Healthc Policy
  • 4.1 J Inflamm Res
  • 2.0 Int J Gen Med
  • 3.4 J Hepatocell Carcinoma
  • 3.0 J Asthma Allergy
  • 2.2 Clin Cosmet Investig Dermatol
  • 2.4 J Multidiscip Healthc



更多详情 >>





已发表论文

肠道微生物群在炎症性肠病肠纤维化中的作用及中医药干预

 

Authors Fang L, Peng H, Tan Z , Deng N, Peng X

Received 13 November 2024

Accepted for publication 10 April 2025

Published 7 May 2025 Volume 2025:18 Pages 5951—5967

DOI http://doi.org/10.2147/JIR.S504827

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Ning Quan

Leyao Fang,1– 3 Huiyi Peng,1– 3 Zhoujin Tan,2,3 Na Deng,2,3 Xinxin Peng1,2 

1The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 2The Domestic First-Class Discipline Construction Project of Chinese Medicine of Hunan University of Chinese Medicine, Changsha, People’s Republic of China; 3School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, People’s Republic of China

Correspondence: Na Deng, School of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People’s Republic of China, Email 243671178@qq.com Xinxin Peng, The First Hospital of Hunan University of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, People’s Republic of China, Email 367053051@qq.com

Abstract: Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory disorder of the intestine, frequently complicated by intestinal fibrosis. As fibrosis progresses, it can result in luminal stricture and compromised intestinal function, significantly diminishing patients’ quality of life. Emerging evidence suggests that gut microbiota and their metabolites contribute to the pathogenesis of IBD-associated intestinal fibrosis by influencing inflammation and modulating immune responses. This review systematically explores the mechanistic link between gut microbiota and intestinal fibrosis in IBD and evaluates the therapeutic potential of traditional Chinese medicine (TCM) interventions. Relevant studies were retrieved from PubMed, Web of Science, Embase, Scopus, CNKI, Wanfang, and VIP databases. Findings indicate that TCM, including Chinese herbal prescriptions and bioactive constituents, can modulate gut microbiota composition and microbial metabolites, ultimately alleviating intestinal fibrosis through anti-inflammatory, immunemodulatory, and anti-fibrotic mechanisms. These insights highlight the potential of TCM as a promising strategy for targeting gut microbiota in the management of IBD-associated fibrosis.

Keywords: inflammatory bowel disease, intestinal fibrosis, intestinal inflammation, gut microbiota, traditional Chinese medicine

Download Article[PDF]